Seok Ki Choi earned his BS and MS degrees both at Seoul National University, Korea, and PhD degree (1994) in Organic Chemistry at Columbia University, NY. His dissertation work under Professor Koji Nakanishi focused on synthesis of biologically active natural products and mode of action studies. He then joined in Professor George M. Whiteside laboratories at HarvardUniversity as postdoctoral fellow where he performed proof of concept studies of polyvalent applications in biological systems focusing on pathogen-cell adhesion. Dr. Choi started his career as research scientist at Theravance at South San Francisco in 1997, and played a significant role in exploring proprietary applications of polyvalent strategy for novel drug discovery. His research efforts led to discovery of several therapeutic candidates in clinical trials including long acting beta-2 adrenergic agonists for treatment of asthma and chronic obstructive pulmonary diseases, hetero-divalent antibacterial agents, and selective 5-HT4 agonists for gastrointestinal motility disorder (chronic constipation). More recently, he actively pursued in the research and early development of antihypertensive dual-acting small molecule inhibitors that target angiotensin II receptor and neutral endopeptidase.
Dr. Choi joined in Michigan Nanotechnology Institute for Medicine and Biological Sciences in late 2008. His research interests focus on integration of polyvalent concept in biologic nanotechnology. His primary research objectives include rational design of nanodevices at molecular level for targeted cellular uptake of anticancer therapeutics, detection and imaging of cancer cells, and exploring its applications in chemical genomics.